tiprankstipranks
Advertisement
Advertisement

TCRX Stock Latest News

TScan downgraded to Market Perform from Outperform at LifeSci Capital
The FlyTScan downgraded to Market Perform from Outperform at LifeSci Capital
1d ago
TCRX
Needham downgrades TScan Therapeutics as company reprioritizes
PremiumThe Fly
Needham downgrades TScan Therapeutics as company reprioritizes
1d ago
TCRX
TScan Therapeutics downgraded to Hold from Buy at Needham
PremiumThe Fly
TScan Therapeutics downgraded to Hold from Buy at Needham
1d ago
TCRX
TScan Therapeutics downgraded to Neutral from Outperform at Wedbush
PremiumThe Fly
TScan Therapeutics downgraded to Neutral from Outperform at Wedbush
1d ago
TCRX
TScan Therapeutics Restructures to Focus on Solid Tumors
PremiumCompany Announcements
TScan Therapeutics Restructures to Focus on Solid Tumors
1d ago
8K
TCRX
TScan Therapeutics to strategically reorganize, reduce workforce by 75%
PremiumThe FlyTScan Therapeutics to strategically reorganize, reduce workforce by 75%
1d ago
TCRX
TScan Therapeutics Faces Loss of Key Amgen Partnership
Premium
Company Announcements
TScan Therapeutics Faces Loss of Key Amgen Partnership
16d ago
8K
TCRX
TScan Therapeutics reports Q2 EPS (23c), consensus (20c)
Premium
The Fly
TScan Therapeutics reports Q2 EPS (23c), consensus (20c)
18d ago
TCRX
Sam Slutsky Maintains Buy Rating and $6 Price Target on ALLOHA-2 Progress and Cohort C Data De-Risking TSC-101 Program
PremiumRatings
Sam Slutsky Maintains Buy Rating and $6 Price Target on ALLOHA-2 Progress and Cohort C Data De-Risking TSC-101 Program
1M ago
TCRX
TScan Therapeutics doses first patient in ALLOHA-2 trial
PremiumThe Fly
TScan Therapeutics doses first patient in ALLOHA-2 trial
1M ago
TCRX
TScan’s TSC-101 Trial: A New Cell Therapy Bet in Transplant Oncology
PremiumCompany Announcements
TScan’s TSC-101 Trial: A New Cell Therapy Bet in Transplant Oncology
1M ago
TCRX
TScan Therapeutics: Early ALLOHA Phase 1 Efficacy and Safety Reinforce Late-Stage Plans; Buy Rating and $6 Price Target Maintained
PremiumRatings
TScan Therapeutics: Early ALLOHA Phase 1 Efficacy and Safety Reinforce Late-Stage Plans; Buy Rating and $6 Price Target Maintained
2M ago
TCRX
TScan Therapeutics: ALLOHA Data, Streamlined Manufacturing Bolster Buy Rating with $7 Price Target Maintained
PremiumRatingsTScan Therapeutics: ALLOHA Data, Streamlined Manufacturing Bolster Buy Rating with $7 Price Target Maintained
2M ago
TCRX
TScan Therapeutics Advances TSC-101 Toward Pivotal Trial
Premium
Company Announcements
TScan Therapeutics Advances TSC-101 Toward Pivotal Trial
2M ago
8K
TCRX
TScan Therapeutics presents data from Cohort C of ALLOHA trial
Premium
The Fly
TScan Therapeutics presents data from Cohort C of ALLOHA trial
2M ago
TCRX
TScan Therapeutics, Cellares enter agreement to evaluate TCS-101 manufacturing
PremiumThe Fly
TScan Therapeutics, Cellares enter agreement to evaluate TCS-101 manufacturing
3M ago
TCRX
TScan Therapeutics Expands Authorized Shares After Stockholder Vote
PremiumCompany Announcements
TScan Therapeutics Expands Authorized Shares After Stockholder Vote
3M ago
8K
TCRX
Buy Rating Reiterated on TSC-101 Ahead of Key ALLOHA Readouts and Pipeline Expansion; $6 Price Target Maintained
PremiumRatings
Buy Rating Reiterated on TSC-101 Ahead of Key ALLOHA Readouts and Pipeline Expansion; $6 Price Target Maintained
4M ago
TCRX
TScan Therapeutics reports Q1 EPS (22c), consensus (17c)
PremiumThe Fly
TScan Therapeutics reports Q1 EPS (22c), consensus (17c)
4M ago
TCRX
TScan Therapeutics Consolidates Finance Leadership After Officer Resignation
PremiumCompany AnnouncementsTScan Therapeutics Consolidates Finance Leadership After Officer Resignation
5M ago
8K
TCRX
Buy 2 ‘Strong Buy’ Biotech Stocks With 400%+ Upside, According to Wall Street
Premium
Market News
Buy 2 ‘Strong Buy’ Biotech Stocks With 400%+ Upside, According to Wall Street
6M ago
CRVO
TCRX
TScan Therapeutics price target raised to $5 from $4 at Wedbush
Premium
The Fly
TScan Therapeutics price target raised to $5 from $4 at Wedbush
6M ago
TCRX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >